Nervgen Pharma (NGEN) Enterprise Value (2024 - 2026)

Nervgen Pharma (NGEN) posted quarterly Enterprise Value of -$12.1 million for Q1 2026, up 23.7% quarter-over-quarter from -$15.8 million in Q4 2025.

Nervgen Pharma (NGEN) Enterprise Value (2024 - 2026) Analysis & Trends

Nervgen Pharma (NGEN) has reported Enterprise Value for 3 consecutive years, with -$12.1 million the latest figure, recorded in Q1 2026.

In Q1 2026, Enterprise Value changed N/A year-over-year to -$12.1 million; the TTM figure through Mar 2026 stood at -$12.1 million (changed N/A YoY), while the FY2025 annual figure was -$15.8 million, down 28.03% from the prior year.
Enterprise Value rose to -$12.1 million in Q1 2026 per NGEN's latest filing, from -$15.8 million in the prior quarter.
Across five years, Enterprise Value topped out at -$12.1 million in Q1 2026 and bottomed at -$15.8 million in Q4 2025.
Historically, Enterprise Value has averaged -$13.4 million across 3 years, with a median of -$12.4 million in 2024.
On a YoY basis, Enterprise Value climbed as much as 28.03% in 2025 and fell as far as 28.03% in 2025.
Nervgen Pharma's Enterprise Value stood at -$12.4 million in 2024, then retreated by 28.03% to -$15.8 million in 2025, then increased by 23.7% to -$12.1 million in 2026.
Business Quant data shows NGEN's Enterprise Value at -$12.1 million in Q1 2026, -$15.8 million in Q4 2025, and -$12.4 million in Q4 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Enterprise Value (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-7.85 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	-7.99 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-5.18 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-5.14 Bn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	-5.10 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-3.31 Bn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	-1.16 Bn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	2.12 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	-18.39 Bn
10	Nervgen Pharma	161.78 Mn	161.78 Mn	-	-62.74 Mn

Download Data